about
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injuryFindings of the first consensus conference on medical emergency teams.Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury.Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study.Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease.Long-term outcome after intensive care: can we protect the kidney?The influence of gender on ICU admittance.Plasma endostatin may improve acute kidney injury risk prediction in critically ill patients.Long-term outcome after acute renal replacement therapy: a narrative review.Novel biomarkers of acute kidney injury and failure: clinical applicability.Early lumbar puncture in adult bacterial meningitis--rationale for revised guidelines.Assessment of plasma endostatin to predict acute kidney injury in critically ill patients.Intraoperative hypotension is associated with myocardial damage in noncardiac surgery: An observational study.Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU.LiFe: a liver injury score to predict outcome in critically ill patients.Understanding renal recovery.Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury.Time dependent influence of host factors on outcome after trauma.Acute kidney injury following coronary artery bypass grafting: early mortality and postoperative complications.ICU admittance by a rapid response team versus conventional admittance, characteristics, and outcome.Continuous renal replacement therapy in septic patients: is it really harmful?Prevalence and sensitivity of MET-criteria in a Scandinavian University Hospital.The deteriorating ward patient: a Swedish-Australian comparison.Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure.Reducing in-hospital cardiac arrests and hospital mortality by introducing a medical emergency team.Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria.Cystatin C is correlated with mortality in patients with and without acute kidney injury.Renal support in critically ill patients with acute kidney injury.Intra-day variability of cystatin C, creatinine and estimated GFR in intensive care patients.Cystatin C: More than a renal function marker.Association of plasma neutrophil gelatinase-associated lipocalin (NGAL) with sepsis and acute kidney dysfunction.Immunoassays distinguishing between HNL/NGAL released in urine from kidney epithelial cells and neutrophils.Impact of sepsis on levels of plasma cystatin C in AKI and non-AKI patients.Pheochromocytoma-Induced Inverted Takotsubo-Like Cardiomyopathy Leading to Cardiogenic Shock Successfully Treated With Extracorporeal Membrane Oxygenation.Limitations of medical treatment among patients attended by the rapid response team.Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100.National Early Warning Score vs Rapid Response Team criteria-Prevalence, misclassification, and outcomeThe Novel PrisMax Continuous Renal Replacement Therapy System in a Multinational, Multicentre Pilot SettingAuthors’ ResponseAcute kidney injury after coronary artery bypass grafting and long-term risk of myocardial infarction and death
P50
Q33753800-136531FF-497F-4C91-8521-060C0B060254Q34552610-9484EB50-1DAD-4826-B131-5E4AD1CE34D4Q35240791-784F2601-8C10-4C98-AB5F-E8C09A4579C3Q35687637-78FB6566-CA3E-4C2A-9E62-4B7906ED0636Q36242756-E86859D6-7A2F-4A06-B1DE-D1375947641EQ36392776-65DF4D2F-8DD1-4CB9-AE5F-C5AACD47BE5BQ36401899-AE2D1990-2B68-44D7-9734-2DE4B933A5D3Q36460290-CE3BCCDE-4512-4268-934F-15E6A865777AQ37957191-85266347-9F08-4C4F-A8CE-CCE0A10A8545Q38050719-4733DB2D-F392-41F4-8DFA-CC505FF39815Q38117663-E148D3A6-C828-4BC4-8C04-1E308FA6AD5EQ38600681-C96AF571-8B74-424A-A39B-ADED03B19417Q39942827-B538263E-7D79-44EC-8E1E-26CB40F5F2BFQ40160349-1E05FB62-5503-41B1-9A72-C5B783F1A8B7Q40945062-3CDFAE98-C794-49A3-B228-93F0990B0238Q41023718-AB16978F-E250-428E-B3BA-FCF549297BCAQ43097129-27845516-3723-4C16-9F4A-B1F24D61805BQ43413693-AE9A9D04-54E0-45F0-8039-EE6B8E04F538Q43796128-1FDEC2F0-C28E-421F-8852-6BE4AF7F3C44Q43990833-A6BD8875-FF5A-407F-92BB-06EBC7BFCBA1Q44096026-EF2A1252-E0A6-4D7A-8044-61023C35EC64Q44118869-38754389-0D60-4AEA-AE3E-F9484FA7A39CQ44528542-B0F31277-E891-4D40-A352-E794B42D6FF7Q44538513-BC1E99C8-04AE-4C3C-BCF7-5FD2A5817AFCQ44871156-DD638E37-12AB-470C-B17C-E91C72A5230DQ45186976-D4CF267B-A78C-4945-AE55-CB3B45129D7CQ46035997-AF49B7AB-3995-4AAD-861F-1C2ACACE834DQ46268130-94CA0560-CB3C-48DC-A066-7E15338D2861Q47418657-D9B29879-990C-40C1-80E6-6A45E5C830C9Q47756154-125EBA55-C8BD-4F3E-8DF6-052C0DBC3ED2Q48012925-3A3313CF-1AFB-4F54-895E-EB1DA6C65A54Q48160781-5BB3637C-24CD-431E-AE02-56D5EA76212DQ48247147-C305B9BE-D5F3-4ED3-8077-7DF19216D830Q48495335-38E516F6-D64F-47DF-9F75-C4510DBE784BQ50763067-03790DF4-5AAD-4004-8B7C-ACDB54E489B1Q51590959-2CB6C163-13B8-4AAF-8BBE-0494B5DE2AC1Q57322369-3E62B34C-42FE-4E22-B7B5-9CBC04337CF2Q57322375-0B310D6E-F118-4DF6-8C91-770894B86268Q57322402-2DD271C1-83EE-40FC-8367-7334E310D7EBQ57322420-C863F383-6D7F-4E50-ADF8-9E94379FC619
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Max Bell
@ast
Max Bell
@en
Max Bell
@es
Max Bell
@nl
Max Bell
@sl
type
label
Max Bell
@ast
Max Bell
@en
Max Bell
@es
Max Bell
@nl
Max Bell
@sl
prefLabel
Max Bell
@ast
Max Bell
@en
Max Bell
@es
Max Bell
@nl
Max Bell
@sl
P106
P1153
7401466555
P21
P31
P496
0000-0001-7464-0324